BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26705257)

  • 1. Identification of novel serum peptides biomarkers for female breast cancer patients in Western China.
    Yang J; Xiong X; Liu S; Zhu J; Luo M; Liu L; Zhao L; Qin Y; Song T; Huang C
    Proteomics; 2016 Mar; 16(6):925-34. PubMed ID: 26705257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.
    Yang J; Yang J; Gao Y; Zhao L; Liu L; Qin Y; Wang X; Song T; Huang C
    PLoS One; 2014; 9(11):e111364. PubMed ID: 25368985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Peptidome Pattern of Breast Cancer Using Magnetic Beads-Based Plasma Fractionation and MALDI-TOF MS: A Case Control Study in Egypt.
    Zaki A; Ramadan RA; Moez P; Ghareeb H; Elkarmouty A
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):175-184. PubMed ID: 30678429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
    Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
    J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
    Boccardo F; Rubagotti A; Nuzzo PV; Argellati F; Savarino G; Romano P; Damonte G; Rocco M; Profumo A
    Int J Cancer; 2015 Nov; 137(10):2394-402. PubMed ID: 25994113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC).
    Yang J; Song YC; Song TS; Hu XY; Guo YM; Li ZF; Dang CX; Huang C
    J Clin Lab Anal; 2012 May; 26(3):148-54. PubMed ID: 22628229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
    Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
    Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein C1 (APOC1), A Candidate Diagnostic Serum Biomarker for Breast Cancer Identified by Serum Proteomics Study.
    Yan Y; Zhou Y; Wang K; Qiao Y; Zhao L; Chen M
    Crit Rev Eukaryot Gene Expr; 2022; 32(4):1-9. PubMed ID: 35695660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis.
    Fan NJ; Gao CF; Zhao G; Wang XL; Liu QY
    Diagn Pathol; 2012 Apr; 7():45. PubMed ID: 22521044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.
    Pietrowska M; Marczak L; Polanska J; Behrendt K; Nowicka E; Walaszczyk A; Chmura A; Deja R; Stobiecki M; Polanski A; Tarnawski R; Widlak P
    J Transl Med; 2009 Jul; 7():60. PubMed ID: 19594898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
    Shevchenko VE; Arnotskaya NE; Zaridze DG
    Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of serum proteomic mass spectrum analysis in breast cancer].
    Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases.
    Terracciano R; Preianò M; Palladino GP; Carpagnano GE; Barbaro MP; Pelaia G; Savino R; Maselli R
    Proteomics; 2011 Aug; 11(16):3402-14. PubMed ID: 21751363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative serum proteomic analysis of serum diagnosis proteins of colorectal cancer based on magnetic bead separation and maldi-tof mass spectrometry.
    Deng BG; Yao JH; Liu QY; Feng XJ; Liu D; Zhao L; Tu B; Yang F
    Asian Pac J Cancer Prev; 2013; 14(10):6069-75. PubMed ID: 24289627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New serum biomarkers for detection of endometriosis using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Zheng N; Pan C; Liu W
    J Int Med Res; 2011; 39(4):1184-92. PubMed ID: 21986120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers screening between preoperative and postoperative patients in pancreatic cancer.
    Li P; Yang J; Ma QY; Wu Z; Huang C; Li XQ; Wang Z
    Asian Pac J Cancer Prev; 2013; 14(7):4161-5. PubMed ID: 23991970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum peptidome patterns of colorectal cancer based on magnetic bead separation and MALDI-TOF mass spectrometry analysis.
    Fan NJ; Gao CF; Wang XL; Zhao G; Liu QY; Zhang YY; Cheng BG
    J Biomed Biotechnol; 2012; 2012():985020. PubMed ID: 23091368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALDI-TOF-MS analysis in low molecular weight serum peptidome biomarkers for NSCLC.
    Song Y; Xu X; Wang N; Zhang T; Hu C
    J Clin Lab Anal; 2022 Apr; 36(4):e24254. PubMed ID: 35212031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and identification of serum protein peak at 6648 m/z as a novel indicator in breast cancer based on mass spectrometry.
    Song D; Yue L; Zhan Y; Zhang J; Yan Z; Fan Y; Yang H; Zhang D; Liu Q; Xia Z; Qin P; Jia J; Yue M; Yu J; Zheng S; Yang F; Wang J
    Discov Med; 2017 May; 23(128):283-294. PubMed ID: 28715644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.